Myeloproliferative Disorders D009196

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Bone Marrow Diseases » Myeloproliferative Disorders

Description

Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.   MeSH

Subtype Terms (8)

Anemia, Myelophthisic
 

Leukemia, Erythroblastic, Acute
7 drugs (6 approved, 1 experimental)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
245 drugs (127 approved, 118 experimental)

Leukemia, Neutrophilic, Chronic
34 drugs (29 approved, 5 experimental)

Leukemoid Reaction
 

Polycythemia Vera
102 drugs (58 approved, 44 experimental)

Primary Myelofibrosis
198 drugs (106 approved, 92 experimental)

Thrombocytosis
11 drugs (9 approved, 2 experimental)


Phase 4 Indicated Drugs (2)

Phase 2 Indicated Drugs (138)

Phase 1 Indicated Drugs (79)


Organization Involved with Phase 4 Indications (1)

Organization Involved with Phase 2 Indications (99)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.